共 142 条
[1]
Molina JR(2008)Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship Mayo Clin Proc 83 584-594
[2]
Yang P(1971)Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182-1186
[3]
Cassivi SD(2011)Hallmarks of cancer: the next generation Cell 144 646-674
[4]
Schild SE(2017)Tumor angiogenesis and vascular normalization: alternative therapeutic targets Angiogenesis 20 409-426
[5]
Adjei AA(2011)Molecular mechanisms and clinical applications of angiogenesis Nature 473 298-307
[6]
Folkman J(2004)Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 391-400
[7]
Hanahan D(2013)The VEGF pathway in lung cancer Cancer Chemother Pharmacol 72 1169-1181
[8]
Weinberg RA(2006)Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med. 355 2542-2550
[9]
Viallard C(2007)FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer Oncologist 12 713-718
[10]
Larrivée B(1997)Endostatin: an endogenous inhibitor of angiogenesis and tumor growth Cell 88 277-285